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Introduction
Breast density has been shown to have a heritable com-
ponent and may serve as a marker of genetic risk 
for breast cancer [1,2]. Other studies [3–8] have dem-
onstrated that breast density is also associated with
hormone exposure, reproductive factors, and dietary
factors. In addition, it is also suggested that women
with higher mammographic densities are at an increased
risk for breast cancer [9,10]. Therefore, it is possible
that increased breast density may be related to genetic
factors, environmental factors, or both.
Until reports from the Women’s Health initiative
addressed the adverse effect of using hormone therapy
(HT) for more than 5 years on breast cancer [11], HT
was increasingly prescribed to postmenopausal women
for the relief of climacteric symptoms as well as for the
prevention of osteoporosis. Several studies have demon-
strated an association between the use of HT and breast
density [8,12,13]. However, certain factors related to the
effects of menopause, which affect breast density, have
not been thoroughly investigated in postmenopausal
women using HT.
If increased mammographic density is causally 
related to breast cancer, it is important to understand
whether certain factors can have an effect on mammo-
graphic density. This will provide information for the
development of individualized treatments with respect
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to breast receptivity to HT and may be useful in identi-
fying postmenopausal women who suffer adverse effects
resulting from HT.
As mentioned above, although the effects of HT on
mammographic density have been well studied, the re-
lationships between other factors and mammographic
density have not been well examined. In this study, we
investigated the association of menopause-related and
hormonal factors with the mammographic density in
postmenopausal women using HT.
Materials and Methods
Study sample
The study sample consisted of 1,415 postmenopausal
women who attended the Keelung Chang Gung Me-
morial Hospital gynecologic clinic from 1994 to 2001.
They had not received HT before and requested HT for
climacteric symptoms. Before beginning HT, all of these
patients received thorough examinations, including ma-
mmography, liver function, lipoprotein metabolism, and
gynecologic evaluations. None of the participants had
contraindications for estrogen or progesterone treat-
ment. Women with the following conditions were ex-
cluded from HT: bleeding due to an undiagnosed cause,
findings suggesting malignant disease of the breast,
known or suspected estrogen-dependent tumors or
fibroids, alcoholism, Rotor or Dubin-Johnson syndrome,
severe liver or kidney disorders, endometrial hyperplasia,
and severe hypertension. In addition, we only enrolled
women who had regular follow-ups and maintained the
same regimen and dosage of HT for at least 2 years
following their first mammogram. In total, this study
comprised 467 women. The remaining women were ex-
cluded for reasons such as discontinuous or irregular
use of HT or follow-ups, changing regimens or dosage
of HT, and evaluation through breast ultrasound.
Among the 467 postmenopausal women, 200
(42.8%) patients had hysterectomies for benign gynecol-
ogical disorders and used only 0.625 mg/day conjugated
estrogen (Premarin, Wyeth-Ayerst Canada Company,
Montreal, Quebec, Canada). The other 267 women were
treated with continuous combined 0.625 mg/day con-
jugated estrogen plus 2.5 mg/day medroxyprogesterone
acetate (Provera, Pharmacia & Upjohn Company,
Kalamazoo, Michigan, USA). Follow-up through mam-
mographic screening was scheduled for every user with
a time interval of 1–2 years following HT.
Measures
From 1994 to 2001, 467 women completed a total 
of 1,438 mammograms using different screening 
techniques including the mediolateral oblique and
craniocaudal views of the bilateral breast. In addition
to the first mammogram prior to the start of HT and the
second screening mammogram after 1 to 2 years of HT,
both of which were completed by all participants, 371
(79.4%) patients had a third mammogram, 281 (60.2%)
had a fourth, 179 (38.3%) had a fifth, and 179 (38.3%)
had a sixth.
Mammograms were reviewed, in a blinded manner,
by a senior radiologist (Dr Y.C. Cheung) who specializes
in breast examinations. Breast densities were coded on
a 4-point scale according to the American College of
Radiology Breast Imaging Reporting and Data System
(BI-RADS) coding [14]. A score of 1 indicates almost
entirely fat; 2 indicates scattered fibroglandular tissue;
3 indicates heterogeneously dense; and 4 indicates
extreme density. Mammographic density was rated
separately for each breast and the breast with the
highest density was then used for analysis.
Statistical analysis
Statistical analysis was evaluated by iSTAT Healthcare
Consulting Co. Ltd. Student t tests were used to assess
the differences in baseline characteristics between those
using estrogen alone versus those using combined
estrogen-progestin. The correlation between breast
density and other variables was also evaluated by the
generalized estimating equation.
Results
From 1994 to 2001, there were 467 women who met the
initial criteria for inclusion into our analysis. Data on age
at start of HT, age at menopause, duration from onset of
menopause to start of HT, body mass index (BMI), dura-
tion of HT use, and regimens (estrogen alone and com-
bined estrogen-progestin) are summarized in Table 1.
At the time of starting HT, the mean age of women
in our sample was 50.4 ± 5.8 years (range, 43–69 years).
As shown in Table 1, although women using estrogen
alone (n = 200) tended to be younger than women
receiving combined estrogen-progestin (n = 267), there
was no significant difference. There were also no sta-
tistical differences in the duration of HT use and BMI
between the women receiving estrogen alone and those
receiving the combination of estrogen-progestin.
Table 2 shows the relationship between breast 
density and variables such as age at start of HT, age at
menopause, years from menopause to start of HT, BMI,
and duration and regimens of HT. After adjustment
for the effects of other variables, age at start of HT 
and BMI were inversely associated with breast density
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(p = 0.003 and < 0.001, respectively). In contrast, the
duration of HT was positively related to mammographic
density (p < 0.001). The Figure shows the association
between different regimens of HT and breast density.
Women using combined estrogen-progestin for more
than 4 years had significant increases in their mean den-
sity scores, compared with those using only estrogen
(p = 0.013). After adjustment for the effects of other
variables, the correlation between breast density and
choice of HT regimens (combined HT vs. estrogen alone)
did not reach the significance level of 0.05. In addition,
age at menopause and years from onset of menopause
to start of HT were not associated with changes in
breast density.
Discussion
Our study of mammographic density concentrated on
postmenopausal women using HT because the effect of
HT on the breast is complex and individualized. In addi-
tion to confirming other previous research, our study
also explored changes in breast density while adjusting
for possible affecting variables, such as BMI, age at
menopause, age at start of HT, and duration from onset
of menopause to the start of HT.
Most previous reports [3,15–19], though not all
[20], found a positive association between the use of
HT and breast density, resembling the well-known asso-
ciation between HT use and the risk of breast cancer.
However, the relationship between HT and mammo-
graphic density must be explored against the back-
ground of changes that normally occur during and after
menopause. The time when involutionary changes nor-
mally occur may be an important factor with respect to
breast receptivity to HT and may be useful in identifying
women who suffer an adverse effect resulting from HT.
In our study, the effect of HT on mammographic den-
sity was inversely associated with age at the initiation
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Table 2. Correlation between changes in breast density and other variables estimated by the method of generalized estimating 
equation (n = 467)*
Variable Value Estimate SE p
Age at start of HT 50.4 ± 5.8 (43–69) −0.0608 0.0201 0.003
Age at menopause 47.1 ± 5.0 (42–59) 0.0393 0.0216 0.069
Duration† 3.3 ± 4.7 0.0393 0.0222 0.076
Regimen Estrogen alone vs. combined HT −0.0308 0.0586 0.599
Year of use of HT 3.5 ± 1.6 0.0449 0.0096 < 0.001
BMI 24.4 ± 3.3 −0.0287 0.0071 < 0.001
*Data are presented as mean ± standard deviation (range); †years from onset of menopause to start of HT. SE = standard error; BMI = body mass index; HT =
hormone therapy.

























Figure. Changes in breast density by pattern of hormone ther-
apy. E = estrogen alone; E + P = combined estrogen-progestin.
Table 1. Baseline characteristics by pattern of hormone therapy (n = 467)*
Estrogen alone Combined HT† p
No. of patients 200 (42.8) 267 (57.2)
Age at start of HT (yr) 49.2 ± 5.6 (43–69) 51.3 ± 5.7 (43–67) 0.066
Age at menopause (yr) 46.2 ± 4.8 (42–56) 47.8 ± 5.1 (43–59) 0.691
Body mass index (kg/m2) 24.9 ± 3.6 24.5 ± 3.4 0.140
Duration from onset of menopause 3.1 ± 4.7 3.6 ± 4.8 0.272
to start of HT (yr)
Duration of HT (yr) 3.2 ± 1.3 3.8 ± 1.8 0.464
*Data are presented as n (%), mean ± standard deviation (range) or mean ± standard deviation; †combined estrogen-progestin. HT = hormone therapy.
of HT. This indicates that the breast may undergo in-
volutionary change after cessation of the menses.
Similar age-specific patterns were reported by two stud-
ies. These found that the relationship between HT and
breast cancer risk was stronger in younger women
[21,22], although this is not always seen [23]. In addi-
tion, the study of Titus-Ernstoff et al [24], as well as
other reports [3,18], showed the impact of current HT
use on breast density with an inverse association in
younger women (> 50 years of age), and a positive asso-
ciation in older women. Since these reports did not
adjust for the effect of HT duration as our study did,
the age-related increase observed in these reports may
reflect a longer HT duration.
In this study, we also found that women with in-
creased BMI had reduced breast densities. This finding
is supported by other studies [25,26] in which one
might expect to find more fatty replacement and less
dense patterns in obese women. In addition, several
reports [21,27,28] found that the risk of breast cancer
with use of either estrogen alone or combined estrogen-
progestin was slightly greater among women with leaner
body masses. The study of Schairer et al [29] observed
that the use of estrogen alone was associated with an
increased risk only among lean women and not among
heavy women, whereas associations with combined use
did not vary by weight. However, excluding the effects
of HT, increased body weight and BMI have been con-
sistently associated with elevated relative risk of breast
cancer, especially in postmenopausal women [30,31].
In this study, we found that the duration of HT was
related to increased mammographic density. Our study
confirmed findings from previous studies demonstrating
an association between using HT and increased breast
density [8,12,18,19,25]. In contrast, two studies de-
monstrated no difference in the breast density associ-
ated with the duration of HT use, suggesting that density
changes, if any, develop relatively soon after HT is
started and then remain stable [3,4]. However, the
positive influence of HT on breast cancer risk is usually
observed in long-term use [21,23,27–29,32]. If the dura-
tion of HT is considered, it is possible that sustained
breast density associated with long-term HT use medi-
ates the relationship between HT and breast cancer
risk. In our previous study [33], the long-term use of
HT was associated with increased incidence of increased
parenchymal breast density, from 8.6% to 18.4% dur-
ing the 7-year follow-up, and the majority of the breast
densities remained at pre-treatment levels. This means
that long-term use of HT induced increased breast
densities in some women. Therefore, in postmenopausal
with increased breast densities after HT, the potential
of exogenous hormones inducing epithelial or stromal
hyperplasia must be considered. If the effect is epithe-
lial hyperplasia, the risk of breast cancer must be taken
into account.
Effects of progesterone on the breast are suggested
by reports that breast density is greater during the luteal
phase of the menstrual cycle [34–36]. In an animal model
for hormone replacement, continuous-combination
estrogen-progestin treatment induced more prolifera-
tion than estrogen alone [37]. Our study showed that,
in long-term HT use without adjustment for the effects
of other variables, an increase in breast density was
much more common and more pronounced among
women receiving combined estrogen-progestin than
among those using estrogen alone. Our data are in
agreement with a number of previous studies [19,38–41].
In the present study, we found that in women using com-
bined estrogen-progestin, the probability of increased
mammographic density was progressively increased as
the duration of administration was extended (from 7.5%
to 22.4%, data not shown). In contrast, women using
estrogen alone did not show an increased incidence of
breast density over an increased duration of HT; the
majority remained at the pre-treatment level. However,
after adjustment for the effects of other variables, the
duration of HT is the only significant factor in the mam-
mographic density increase, and the effect of proges-
terone becomes non-significant. If increased breast
density is associated with an increased risk of breast
cancer, it is compatible with epidemiological studies
[27] showing that the risk of breast cancer increases
with long-term HT use.
The present results suggest that age at menopause
and years from menopause to start of hormone ther-
apy are not associated with the changes of breast den-
sity in postmenopausal HT, after adjustment for other
variables. Similar results from other studies revealed
that age at menopause was not significantly associ-
ated with percentage density [20,42], and women
who started HT after the onset of menopause did not
appear to be different from non-HT users with respect
to high-risk patterns [25].
In conclusion, the effects of HT on the breast, as re-
flected by mammography, may be influenced by factors
associated with menopause. A longer duration of HT,
especially in younger postmenopausal women and those
with lower BMI, results in a greater percentage of women
who develop more glandular tissue, as seen in mammog-
raphy. The implications of additional glandular tissue
are unknown, but it might have an impact on the sen-
sitivity of mammography or alter the risk for subsequent
breast cancer. For patients needing long-term HT, we
recommend close follow-up by mammography and even
more detailed evaluations of the potential of exogenous
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hormones inducing epithelial hyperplasia in those with
increased breast densities.
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